Search Results

PharmaJet® announced the formation of two Scientific Advisory Boards comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping.

PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced the start of the first human clinical trial for a Venezuelan Equine Encephalitis (VEE) vaccine delivered with PharmaJet Precision Delivery Systems.

PharmaJet,® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery, announced that Marie Mazur, PharmD, has been appointed Chair of the Board of Directors.

In a review article recently published in Vaccines Journal, Dr. Carmen Ledesma-Feliciano, Scientific Affairs Manager at PharmaJet, referencing over 25 studies, discusses multiple injection delivery methods including PharmaJet’s needle-free precision delivery systems, which enhance the clinical performance of DNA-based vaccines.

PharmaJet,® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery, announced that Nanette Cocero, Ph.D., has been appointed to its Board of Directors.

PharmaJet® announced that its Tropis® System is now the exclusive intradermal delivery system for two authorized novel Covid-19 vaccines: This press release features multimedia.